

Efstathios Kastritis

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/1528920/publications.pdf](https://exaly.com/author-pdf/1528920/publications.pdf)

Version: 2025-02-01

571

PR articles

23,567

PR citations

18011

59

PR h-index

7960

147

g-index

627

documents

28840

doc citations

15613

66

h-index

38308

citing authors

#	ARTICLE	IF	CITATIONS
1	VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BSMG). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, e71-e81.	1.0	2
2	Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, e310-e318.	1.0	1
3	Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Hematology</i> , 2025, 100, 427-438.	6.5	15
4	Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, e359-e365.	1.0	1
5	Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First-Line Treatment. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2025, 35, .	3.2	2
6	Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer. <i>Nutrients</i> , 2025, 17, 556.	4.5	2
7	Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2025, 32, 193-195.	4.6	1
8	Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2025, 32, 139-144.	4.6	2
9	Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenström's Macroglobulinemia. <i>Nature Communications</i> , 2025, 16, .	13.7	12
10	Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. <i>Blood</i> , 2025, 145, 2353-2360.	4.2	12
11	Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, 532-538.	1.0	1
12	Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome. <i>Blood Cancer Journal</i> , 2025, 15, .	5.5	2
13	Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice. <i>Journal of Clinical Medicine</i> , 2025, 14, 2224.	2.5	3
14	Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring. <i>Blood Advances</i> , 2025, 9, 4444-4447.	5.0	8
15	Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors. <i>Seminars in Hematology</i> , 2025, 62, 113-119.	3.1	2
16	Report of Consensus Panel 3 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with high-risk disease. <i>Seminars in Hematology</i> , 2025, 62, 90-105.	3.1	5
17	Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimens. <i>Blood Advances</i> , 2025, 9, 3771-3779.	5.0	6
18	Report of Consensus Panel 1 from the 12th International Workshop on the management of patients with IgM and Waldenström's Macroglobulinemia related neuropathy. <i>Seminars in Hematology</i> , 2025, 62, 76-84.	3.1	4

#	ARTICLE	IF	CITATIONS
19	A prospective study of small fiber neuropathy in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2025, 32, 211-217.	4.6	2
20	Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal protein. <i>British Journal of Haematology</i> , 2025, 206, 1849-1852.	2.7	0
21	Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL Amyloidosis. <i>American Journal of Hematology</i> , 2025, 100, 1305-1313.	6.5	0
22	Genomic landscape of multiple myeloma and its precursor conditions. <i>Nature Genetics</i> , 2025, 57, 1493-1503.	25.2	20
23	Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. <i>Blood Cancer Journal</i> , 2025, 15, .	5.5	4
24	Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 Patients. <i>American Journal of Hematology</i> , 2025, 100, 1334-1342.	6.5	3
25	Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Cancers</i> , 2025, 17, 1943.	3.8	4
26	Second Primary Malignancies and Disease Transformation in Patients With Symptomatic Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, e818-e825.e2.	1.0	1
27	The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. <i>Leukemia</i> , 2025, 39, 2226-2236.	7.7	3
28	Pomalidomide, Cyclophosphamide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2025, 25, e1077-e1085.	1.0	2
29	Transthyretin amyloidosis cardiomyopathy in Greece: Clinical insights from the National Referral Center. <i>Hellenic Journal of Cardiology</i> , 2024, 79, 25-34.	1.7	9
30	Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series. <i>Blood</i> , 2024, 143, 734-737.	4.2	37
31	Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2024, 25, 698-707.	1.4	8
32	Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients. <i>HemaSphere</i> , 2024, 8, .	0.4	7
33	Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA. <i>American Journal of Hematology</i> , 2024, 99, 396-407.	6.5	16
34	Thrombotic and bleeding complications in patients with AL amyloidosis. <i>British Journal of Haematology</i> , 2024, 204, 1816-1824.	2.7	5
35	Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity. <i>Blood Cancer Journal</i> , 2024, 14, .	5.5	3
36	Single-cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients. <i>HemaSphere</i> , 2024, 8, .	0.4	7

#	ARTICLE	IF	CITATIONS
37	Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial tRNA ^{Phe} results in patients' poor treatment outcome. <i>British Journal of Haematology</i> , 2024, 204, 1790-1800.	2.7	9
38	A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy. <i>Leukemia and Lymphoma</i> , 2024, 65, 857-859.	1.4	1
39	Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2024, 5, 146-152.	4.9	7
40	Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2024, 24, 468-477.	1.0	5
41	Renal Response Criteria for Clinical Trials in Amyloid Light Chain Amyloidosis. <i>Kidney International Reports</i> , 2024, 9, 1986-1994.	2.5	3
42	circRNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma. <i>EJHaem</i> , 2024, 5, 677-689.	1.6	6
43	Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma. <i>American Journal of Hematology</i> , 2024, 99, 1887-1896.	6.5	10
44	Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group. <i>American Journal of Hematology</i> , 2024, 99, 1897-1905.	6.5	14
45	Necrotizing Laryngitis in Patients with Hematologic Disease: The First Case-Report Due to PDR <i>Acinetobacter baumannii</i> and Literature Review. <i>Microorganisms</i> , 2024, 12, 1382.	3.8	0
46	TEMPI syndrome: difficult to diagnose, "easy" to treat?. <i>Annals of Hematology</i> , 2024, 103, 3787-3793.	1.5	2
47	Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. <i>JAMA Oncology</i> , 2024, 10, 1362.	14.4	18
48	Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG). <i>Leukemia and Lymphoma</i> , 2024, 65, 2064-2067.	1.4	1
49	Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal Gammopathies. <i>Journal of Clinical Medicine</i> , 2024, 13, 6461.	2.5	1
50	Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease-Protein-Drug Network. <i>Pharmaceuticals</i> , 2024, 17, 1736.	4.2	0
51	Optimal use of BTK inhibitors in Waldenström's macroglobulinemia: combination or single drug approach?. <i>Therapeutic Advances in Hematology</i> , 2024, 15, .	2.9	0
52	Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 3-17.	4.6	78
53	Cardiac mechanics in response to proteasome inhibition: a prospective study. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 643-652.	1.4	9
54	Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: Prognostic and More. <i>Journal of Clinical Oncology</i> , 2023, 41, 708-710.	16.9	14

#	ARTICLE	IF	CITATIONS
55	Pulmonary function tests reveal unrecognised lung dysfunction and have independent prognostic significance in patients with systemic AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 153-160.	4.6	0
56	Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations. <i>Blood Advances</i> , 2023, 7, 971-981.	5.0	6
57	Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. <i>International Journal of Cancer</i> , 2023, 152, 1947-1963.	4.3	9
58	Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis. <i>Hematology</i> , 2023, 28, .	1.3	9
59	Monoclonal Gammopathy of Thrombotic Significance. <i>Cancers</i> , 2023, 15, 480.	3.8	23
60	Diagnostic and Prognostic Value of Non-late Gadolinium Enhancement Cardiac Magnetic Resonance Parameters in Cardiac Amyloidosis. <i>Current Problems in Cardiology</i> , 2023, 48, 101573.	3.0	11
61	The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. <i>Blood Cancer Journal</i> , 2023, 13, .	5.5	42
62	Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy. <i>Blood Cancer Journal</i> , 2023, 13, .	5.5	16
63	Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. <i>JCI Insight</i> , 2023, 8, .	5.4	13
64	Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 268-278.	4.6	15
65	Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies. <i>JACC: CardioOncology</i> , 2023, 5, 1-21.	4.6	80
66	Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. <i>Lancet Haematology</i> , 2023, 10, e203-e212.	9.6	61
67	Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. <i>Annals of Hematology</i> , 2023, 102, 863-876.	1.5	12
68	Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group. <i>American Journal of Hematology</i> , 2023, 98, 730-738.	6.5	23
69	Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study. <i>Viruses</i> , 2023, 15, 704.	3.2	13
70	Venetoclax in Relapse/Refractory AL Amyloidosis: A Multicenter International Retrospective Real-World Study. <i>Cancers</i> , 2023, 15, 1710.	3.8	24
71	Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease. <i>Hematological Oncology</i> , 2023, 41, 725-732.	2.1	11
72	Report of consensus panel 1 from the 11th International Workshop on Waldenström's Macroglobulinemia on management of symptomatic, treatment-naïve patients. <i>Seminars in Hematology</i> , 2023, 60, 73-79.	3.1	25

#	ARTICLE	IF	CITATIONS
73	miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. <i>Journal of Translational Medicine</i> , 2023, 21, .	6.4	14
74	Patterns of target organ amyloid deposition in patients with AL amyloidosis; role for diagnosis and prognosis. <i>Leukemia and Lymphoma</i> , 2023, 64, 1212-1215.	1.4	1
75	Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 502-512.	2.5	4
76	Proteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 689-705.	2.2	3
77	The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. <i>Hellenic Journal of Cardiology</i> , 2023, 73, 73-80.	1.7	11
78	Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies. <i>European Journal of Haematology</i> , 2023, 111, 271-278.	1.8	11
79	Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. <i>Blood</i> , 2023, 142, 1208-1218.	4.2	64
80	Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2023, 24, e293-e311.	27.4	90
81	Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 11829.	4.4	13
82	Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 123.	2.7	5
83	MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges. <i>Hemato</i> , 2023, 4, 259-272.	1.0	2
84	Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. <i>Neurology and Therapy</i> , 2023, 12, 1759-1775.	3.8	13
85	Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 844-849.	1.0	6
86	Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2023, 64, 2140-2147.	1.4	13
87	Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies. <i>HemaSphere</i> , 2023, 7, e975.	0.4	4
88	The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1659-1668.	1.6	10
89	Utilization and tolerance of beta-blockers among patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 31-37.	4.6	10
90	Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 656-669.	1.9	8

#	ARTICLE	IF	CITATIONS
91	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	5.0	14
92	Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 1-7.	4.6	99
93	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	3.4	8
94	The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines, 2022, 10, 209.	3.4	20
95	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	4.2	45
96	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood, 2022, 139, 1409-1412.	4.2	34
97	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	3.4	24
98	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	1.0	5
99	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	0.4	18
100	High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Advances, 2022, 6, 3655-3658.	5.0	9
101	Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. American Journal of Hematology, 2022, 97, 719-730.	6.5	9
102	The utility of splenic imaging parameters in cardiac magnetic resonance for the diagnosis of immunoglobulin light-chain amyloidosis. Insights Into Imaging, 2022, 13, .	3.7	9
103	Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma. Radiology, 2022, 304, 137-144.	8.7	36
104	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	4.7	27
105	Monoclonal antibody-based therapies for Waldenström's macroglobulinemia. Leukemia Research Reports, 2022, 17, 100324.	0.4	1
106	Immunogenic Cell Death, DAMPs and Prothymosin ± as a Putative Anticancer Immune Response Biomarker. Cells, 2022, 11, 1415.	4.7	73
107	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	2.5	9
108	Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study âœREBUILDâœ. Cancers, 2022, 14, 2768.	3.8	16

#	ARTICLE	IF	CITATIONS
109	Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls. <i>Journal of Clinical Medicine</i> , 2022, 11, 3355.	2.5	11
110	Determining patterns of vascular function and structure in wild-type transthyretin cardiac amyloidosis. A comparative study. <i>International Journal of Cardiology</i> , 2022, 363, 102-110.	2.2	3
111	Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. <i>American Journal of Hematology</i> , 2022, 97, 1142-1149.	6.5	28
112	SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies. <i>American Journal of Hematology</i> , 2022, 97, 1300-1308.	6.5	15
113	Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy. <i>HemaSphere</i> , 2022, 6, e764.	0.4	25
114	Immune Checkpoint Inhibitors™ Associated Renal Toxicity: A Series of 12 Cases. <i>Journal of Clinical Medicine</i> , 2022, 11, 4786.	2.5	12
115	COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns. <i>Trends in Molecular Medicine</i> , 2022, 28, 800-802.	7.4	5
116	Cardiopulmonary Exercise Physiology in AL Amyloidosis Patients with Cardiac Involvement and Its Association with Cardiac Imaging Parameters. <i>Journal of Clinical Medicine</i> , 2022, 11, 5437.	2.5	2
117	Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity. <i>Aging Cell</i> , 2022, 21, .	6.8	20
118	Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis. <i>JACC: CardioOncology</i> , 2022, 4, 474-487.	4.6	17
119	Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. <i>Leukemia</i> , 2022, 37, 388-395.	7.7	38
120	Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenström's Macroglobulinemia after BNT162b2 Booster Vaccination. <i>Cancers</i> , 2022, 14, 5816.	3.8	15
121	Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 6216.	3.8	14
122	Next generation flow cytometry for MRD detection in patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 19-23.	4.6	31
123	Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 3-11.	4.6	28
124	Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. <i>British Journal of Haematology</i> , 2021, 193, 113-118.	2.7	28
125	Screening for Gaucher disease among patients with plasma cell dyscrasias. <i>Leukemia and Lymphoma</i> , 2021, 62, 761-763.	1.4	3
126	Cardiac amyloidosis presenting with coronary artery embolization. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, .	1.1	1

#	ARTICLE	IF	CITATIONS
127	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, .	10.9	219
128	Mutation-dependent treatment approaches for patients with complex multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 189-201.	0.9	0
129	Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. <i>Leukemia</i> , 2021, 35, 1418-1427.	7.7	27
130	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.8	4
131	Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. <i>Cancers</i> , 2021, 13, 1257.	3.8	14
132	SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. <i>Vaccines</i> , 2021, 9, 207.	2.9	14
133	Exercise-Induced Changes in Tumor Growth via Tumor Immunity. <i>Sports</i> , 2021, 9, 46.	2.2	19
134	Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 Infection. <i>Microorganisms</i> , 2021, 9, 546.	3.8	19
135	Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation. <i>American Journal of Roentgenology</i> , 2021, 216, 742-751.	4.1	19
136	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	4.2	139
137	A randomized phase 3 study of ixazomibâ€“dexamethasone versus physicianâ€™s choice in relapsed or refractory AL amyloidosis. <i>Leukemia</i> , 2021, 36, 225-235.	7.7	49
138	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	1.0	15
139	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	4.2	46
140	A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 3877.	3.8	16
141	Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review. <i>Journal of Infection</i> , 2021, 83, 1-16.	2.8	160
142	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	2.9	26
143	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2021, 22, 319-323.	2.8	35
144	The Utility of Non-LGE Cardiac Magnetic Resonance Imaging Parameters in the Diagnosis of Cardiac Amyloidosis. <i>Heart Lung and Circulation</i> , 2021, 30, e137-e138.	0.9	2

#	ARTICLE	IF	CITATIONS
145	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	34.6	544
146	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	0.4	7
147	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	4.7	42
148	Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients. <i>Cancers</i> , 2021, 13, 4047.	3.8	19
149	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. <i>BMC Medicine</i> , 2021, 19, .	7.1	57
150	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, .	5.5	116
151	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	3.8	46
152	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	5.0	43
153	Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2021, 28, 259-266.	4.6	20
154	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.5	23
155	Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2021, 798, 149014.	8.4	115
156	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.3	20
157	Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2021, 26, 861-879.	3.3	25
158	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 26.	3.2	34
159	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. <i>Life</i> , 2021, 11, 1077.	2.6	26
160	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	2.9	13
161	Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection. <i>Frontiers in Immunology</i> , 2021, 12, .	4.9	13
162	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 25, 117-118.	4.0	9

#	ARTICLE	IF	CITATIONS
163	Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study. <i>Cancers</i> , 2021, 13, 5057.	3.8	9
164	Biomarkers in AL Amyloidosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10916.	4.4	19
165	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , 2021, 8, e934-e946.	9.6	60
166	miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. <i>British Journal of Cancer</i> , 2021, 126, 79-90.	5.5	18
167	Daratumumab plus CyBORd for patients with newly diagnosed light chain (AL) amyloidosis. <i>Therapeutic Advances in Hematology</i> , 2021, 12, .	2.9	6
168	P-127: Patients with Multiple Myeloma on treatment with Anti-CD38 or Anti-BCMA agents have a suboptimal humoral response following COVID-19 vaccination. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S104.	1.0	0
169	De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment. <i>HemaSphere</i> , 2021, 5, e665.	0.4	1
170	tRNA Derivatives in Multiple Myeloma: Investigation of the Potential Value of a tRNA-Derived Molecular Signature. <i>Biomedicines</i> , 2021, 9, 1811.	3.4	9
171	Daratumumab for Immunoglobulin Light Chain Amyloidosis. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 79.	0.2	0
172	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13144.	4.4	22
173	Multiple myeloma: Role of autologous transplantation. <i>Cancer Treatment Reviews</i> , 2020, 82, 101929.	9.6	56
174	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , 2020, 7, e112-e121.	9.6	148
175	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	9.6	132
176	Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. <i>Life</i> , 2020, 10, 214.	2.6	31
177	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. <i>Blood Cancer Journal</i> , 2020, 10, .	5.5	25
178	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Cancers</i> , 2020, 12, 2864.	3.8	27
179	Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction. <i>Journal of Clinical Medicine</i> , 2020, 9, 3201.	2.5	1
180	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, .	5.5	239

#	ARTICLE	IF	CITATIONS
181	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2006.	3.8	18
182	Organ-specific manifestations of COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 20, 493-506.	2.8	426
183	Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2020, 38, 3252-3260.	16.9	138
184	Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5185.	4.4	22
185	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. <i>Leukemia and Lymphoma</i> , 2020, 61, 3247-3250.	1.4	4
186	Response of an oncology unit in the midst of the COVID-19 outbreak. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1947-1952.	0.9	2
187	Emerging drugs for the treatment of Waldenström macroglobulinemia. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 433-444.	2.3	3
188	Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management. <i>HemaSphere</i> , 2020, 4, .	0.4	46
189	MM-167: Phenotypic and Prognostic Evaluation of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Detected with Next-Generation Flow Cytometry (NGF). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S297-S298.	1.0	0
190	Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, .	5.5	34
191	Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3245.	3.8	29
192	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	2.7	20
193	Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period. <i>Annals of Hematology</i> , 2020, 99, 1257-1264.	1.5	16
194	Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2246-2249.	1.4	0
195	Efficacy of Panobinostat for the Treatment of Multiple Myeloma. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	3.9	65
196	Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, .	5.5	20
197	Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome. <i>HemaSphere</i> , 2020, 4, .	0.4	23
198	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. <i>American Journal of Hematology</i> , 2020, 95, 465-471.	6.5	15

#	ARTICLE	IF	CITATIONS
199	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. <i>Rheumatology International</i> , 2020, 40, 1353-1360.	2.4	37
200	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. <i>European Journal of Cancer</i> , 2020, 126, 125-135.	4.9	62
201	Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 103-110.	4.6	20
202	Early Relapse After Autologous Transplant Is Associated With Very Poor Survival and Identifies an Ultra-High-Risk Group of Patients With Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 445-452.	1.0	42
203	Hematological findings and complications of COVID-19. <i>American Journal of Hematology</i> , 2020, 95, 834-847.	6.5	1,540
204	Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1049-1061.	1.5	41
205	Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1251-1255.	1.5	27
206	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. <i>Blood Cancer Journal</i> , 2020, 10, .	5.5	26
207	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 830-844.	5.0	72
208	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2020, 21, 167-179.	2.8	284
209	Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece. <i>Medicine (United States)</i> , 2020, 99, e23845.	1.2	22
210	Daratumumab plus CyBORd for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. <i>Blood</i> , 2020, 136, 71-80.	4.2	193
211	Liver and Gastrointestinal Involvement. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, e1-e13.	2.2	8
212	Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. <i>Circulation Research</i> , 2019, 125, 744-758.	13.2	31
213	Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. <i>Journal of Blood Medicine</i> , 2019, Volume 10, 291-300.	4.4	13
214	Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 921-928.	2.5	8
215	Non-ethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 8010-8018.	4.0	6
216	How I treat Waldenström's macroglobulinemia. <i>Blood</i> , 2019, 134, 2022-2035.	4.2	91

#	ARTICLE	IF	CITATIONS
217	Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 52-53.	4.6	6
218	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. <i>BMC Medical Genetics</i> , 2019, 20, .	1.8	14
219	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	7.7	98
220	A 50-Year-Long Study of Waldenström Macroglobulinemia. <i>Mayo Clinic Proceedings</i> , 2019, 94, 394-396.	3.7	1
221	Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. <i>Scientific Reports</i> , 2019, 9, .	3.4	29
222	Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. <i>Annals of Hematology</i> , 2019, 98, 1427-1434.	1.5	10
223	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. <i>American Journal of Hematology</i> , 2019, 94, .	6.5	12
224	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. <i>HemaSphere</i> , 2019, 3, e300.	0.4	29
225	Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. <i>Blood Advances</i> , 2019, 3, 4095-4103.	5.0	21
226	Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. <i>Blood Advances</i> , 2019, 3, 3002-3009.	5.0	51
227	Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy. <i>Medicine (United States)</i> , 2019, 98, 1078-1084.	1.2	10
228	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 23-28.	1.0	3
229	Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. <i>American Journal of Hematology</i> , 2019, 94, 400-407.	6.5	26
230	Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. <i>Blood</i> , 2019, 133, 710-723.	4.2	111
231	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	4.3	13
232	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 619-628.	1.4	15
233	Cardiac amyloidosis: in search of the ideal diagnostic tool. <i>Herz</i> , 2019, 46, 9-14.	0.8	9
234	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, , .	7.7	9

#	ARTICLE	IF	CITATIONS
235	How We Manage Patients with Plasmacytomas. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 227-235.	2.8	12
236	Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. <i>Blood</i> , 2018, 131, 1568-1575.	4.2	57
237	Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 431-437.	1.0	5
238	Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. <i>Blood Cancer Journal</i> , 2018, 8, .	5.5	45
239	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. <i>Leukemia and Lymphoma</i> , 2018, 59, 2002-2004.	1.4	6
240	The role of ibrutinib in Waldenström macroglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 85-89.	1.0	0
241	The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. <i>Blood</i> , 2018, 131, 464-467.	4.2	59
242	Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2018, 59, 983-987.	1.4	5
243	Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 234-241.	4.6	30
244	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. <i>Blood Cancer Journal</i> , 2018, 8, .	5.5	31
245	Cardio-oncology: A Focus on Cardiotoxicity. <i>European Cardiology Review</i> , 2018, 13, 64.	2.3	93
246	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv41-iv50.	10.0	74
247	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	2.0	30
248	Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S250-S251.	1.0	1
249	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	7.7	179
250	Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. <i>Blood Cancer Journal</i> , 2018, 8, .	5.5	43
251	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <i>New England Journal of Medicine</i> , 2018, 378, 2399-2410.	34.6	329
252	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <i>Lancet Haematology</i> , the, 2018, 5, e299-e309.	9.6	48

#	ARTICLE	IF	CITATIONS
253	Proteasome Inhibitors in Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 829-840.	2.2	11
254	Monoclonal Antibodies for Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 841-852.	2.2	0
255	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.7	92
256	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	7.7	45
257	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, .	5.5	33
258	Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.	1.0	25
259	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2018, 15, 45-59.	32.8	471
260	How I treat rituximab refractory patients with WM. <i>Oncotarget</i> , 2018, 9, 36824-36825.	0.3	6
261	Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. <i>Oncotarget</i> , 2018, 9, 12536-12537.	0.3	1
262	Emerging treatment approaches for myeloma-related bone disease. <i>Expert Review of Hematology</i> , 2017, 10, 217-228.	2.0	14
263	Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. <i>Blood Cancer Journal</i> , 2017, 7, e571-e571.	5.5	40
264	Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. <i>Blood Cancer Journal</i> , 2017, 7, e570-e570.	5.5	33
265	Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. <i>American Journal of Hematology</i> , 2017, 92, 632-639.	6.5	63
266	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 241-250.	27.4	225
267	Current treatment options and investigational drugs for Waldenström's Macroglobulinemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 197-205.	3.9	12
268	Daratumumab combinations: what can we learn?. <i>Blood</i> , 2017, 130, 957-958.	4.2	3
269	Clonal evolution is a prognostic factor for the clinical progression of monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2017, 7, e597-e597.	5.5	9
270	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. <i>European Journal of Haematology</i> , 2017, 99, 449-458.	1.8	7

#	ARTICLE	IF	CITATIONS
271	Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. Bone Marrow Transplantation, 2017, 52, 1537-1542.	2.3	2
272	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. European Journal of Haematology, 2017, 99, 409-414.	1.8	43
273	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. Annals of Hematology, 2017, 96, 1707-1714.	1.5	11
274	An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 2017, 18, 1883-1897.	2.1	28
275	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Leukemia and Lymphoma, 2017, 58, 1506-1508.	1.4	9
276	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. Radiology, 2017, 282, 484-493.	8.7	92
277	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematological Oncology, 2017, 35, 734-740.	2.1	7
278	Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. Scientific Reports, 2017, 7, .	3.4	17
279	Cardiac and renal complications of carfilzomib in patients with multiple myeloma. Blood Advances, 2017, 1, 449-454.	5.0	102
280	Disease control should be the goal of therapy for WM patients. Blood Advances, 2017, 1, 2483-2485.	5.0	5
281	Recent advances in the management of AL Amyloidosis. British Journal of Haematology, 2016, 172, 170-186.	2.7	94
282	Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. American Journal of Hematology, 2016, 91, 499-502.	6.5	85
283	Proteasome inhibitor associated thrombotic microangiopathy. American Journal of Hematology, 2016, 91, .	6.5	109
284	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American Journal of Hematology, 2016, 91, 575-580.	6.5	115
285	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	2.0	24
286	Emerging antibodies for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs, 2016, 21, 225-237.	2.3	26
287	Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 335-340.	1.0	18
288	Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood, 2016, 128, 405-409.	4.2	45

#	ARTICLE	IF	CITATIONS
289	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , 2016, 128, 1321-1328.	4.2	172
290	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8787-8803.	5.6	47
291	Current therapy guidelines for Waldenstrom's macroglobulinaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 194-205.	1.7	5
292	High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e482-e482.	5.5	20
293	TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. <i>British Journal of Haematology</i> , 2016, 172, 44-47.	2.7	11
294	Current treatments for renal failure due to multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2165-2177.	2.1	32
295	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	27.4	2,576
296	Managing renal complications in multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 839-850.	2.0	22
297	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	2.7	71
298	Carfilzomib for treating myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 989-999.	1.0	2
299	Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. <i>Blood Cancer Journal</i> , 2016, 6, e428-e428.	5.5	25
300	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	3.4	30
301	Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance. <i>Leukemia and Lymphoma</i> , 2016, 57, 1382-1388.	1.4	14
302	Neutrophil Gelatinase-Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 29-35.	1.0	17
303	Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with Waldenström's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years. <i>Blood</i> , 2016, 128, 2957-2957.	4.2	1
304	Pomalidomide with Low Dose Dexamethasone Is Effective Irrespective of Primary or Secondary Resistance to Lenalidomide but the IMiD-Free Interval Is Important. <i>Blood</i> , 2016, 128, 3310-3310.	4.2	1
305	Cardiac and Renal Complications of Carfilzomib Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 4491-4491.	4.2	2
306	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 646-646.	4.2	39

#	ARTICLE	IF	CITATIONS
307	Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis. <i>Blood</i> , 2016, 128, 648-648.	4.2	1
308	Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. <i>Clinical Nephrology</i> , 2016, 85 (2016), 44-54.	0.7	8
309	Circulating Adiponectin and Markers of Endothelial and Cardiovascular Dysfunction Correlate with Disease Burden in Newly Diagnosed Patients with Multiple Myeloma; Increase of Adiponectin after Bortezomib- and IMiD-Based Regimens. <i>Blood</i> , 2016, 128, 4446-4446.	4.2	0
310	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. <i>Blood</i> , 2016, 128, 4488-4488.	4.2	0
311	Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death. <i>Blood</i> , 2016, 128, 2954-2954.	4.2	0
312	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	4.2	0
313	Indirubins: A Potential Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 3259-3259.	4.2	0
314	Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents. <i>Blood</i> , 2016, 128, 4490-4490.	4.2	0
315	Addition of Cyclophosphamide and Higher Doses of Dexamethasone Do Not Improve Outcomes of Patients with AL Amyloidosis Treated with Bortezomib. <i>Blood</i> , 2016, 128, 4500-4500.	4.2	0
316	Outcomes of Newly Diagnosed Myeloma Patients Requiring Dialysis: Dialysis Independence Is Associated with Rapid Myeloma Response and Predicts for Longer Survival. <i>Blood</i> , 2016, 128, 4492-4492.	4.2	0
317	Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. <i>American Journal of Hematology</i> , 2015, 90, .	6.5	56
318	Treatment options for relapsed and refractory multiple myeloma. <i>Blood</i> , 2015, 125, 3085-3099.	4.2	152
319	Diagnosis of monoclonal gammopathy of renal significance. <i>Kidney International</i> , 2015, 87, 698-711.	5.3	388
320	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. <i>Leukemia and Lymphoma</i> , 2015, 56, 1723-1726.	1.4	21
321	Amyloid-Beta (1-40) and the Risk of Death From Cardiovascular Causes in Patients With Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 904-916.	2.3	125
322	Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. <i>Blood Cancer Journal</i> , 2015, 5, e319-e319.	5.5	16
323	Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. <i>Annals of Hematology</i> , 2015, 94, 2033-2042.	1.5	52
324	Generation of a Large Observational Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenström's Macroglobulinemia. <i>Blood</i> , 2015, 126, 2096-2096.	4.2	3

#	ARTICLE	IF	CITATIONS
325	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015, 126, 4178-4178.	4.2	12
326	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	4.2	4
327	Thrombotic Microangiopathy in Multiple Myeloma. <i>Blood</i> , 2015, 126, 5317-5317.	4.2	3
328	Bortezomib-Based Triplets Are Associated with a High Probability of Dialysis Independence and Rapid Renal Recovery in Newly Diagnosed Myeloma Patients with Severe Renal Failure or Those Requiring Dialysis. <i>Blood</i> , 2015, 126, 1832-1832.	4.2	0
329	Analysis of Molecular-Cellular Responses to Proteasome Inhibitors in Multiple Myeloma Patients; A Translational Approach of Proteasome Inhibitors In Vivo Effects from the Drosophila Experimental Model to Humans. <i>Blood</i> , 2015, 126, 3250-3250.	4.2	0
330	The Finding of Del 17p in Marrow Plasma Cells from Patients with Light-Chain Amyloidosis (AL) May Confer a Worse Prognosis. <i>Blood</i> , 2015, 126, 3049-3049.	4.2	0
331	Prospective Evaluation of Blood Pressure Monitoring and Baroreceptor Reflex Sensitivity (BRS) in Patients with AL Amyloidosis: Prognostic and Pathophysiologic Implications. <i>Blood</i> , 2015, 126, 3054-3054.	4.2	1
332	Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. <i>Blood</i> , 2015, 126, 4251-4251.	4.2	0
333	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. <i>Blood</i> , 2015, 126, 1074-1074.	4.2	0
334	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015, 126, 4188-4188.	4.2	2
335	Real-World Prospective Evaluation of Different Geriatric Assessment Tools in Unselected Elderly Patients with Symptomatic Myeloma. <i>Blood</i> , 2015, 126, 4242-4242.	4.2	0
336	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	1.4	61
337	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.	1.8	38
338	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	7.7	66
339	The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. <i>Leukemia</i> , 2014, 28, 2402-2403.	7.7	131
340	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	27.4	4,298
341	Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e179-e181.	1.0	8
342	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. <i>American Journal of Hematology</i> , 2014, 89, 34-40.	6.5	38

#	ARTICLE	IF	CITATIONS
343	Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients. American Journal of Hematology, 2014, 89, 803-808.	6.5	61
344	Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Annals of Oncology, 2014, 25, 195-200.	10.0	144
345	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	4.2	158
346	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. Blood, 2014, 124, 2113-2113.	4.2	3
347	Growth Differentiation Factor-15 in Patients with Light Chain (AL) Amyloidosis Has Independent Prognostic Significance and Adds Prognostic Information Related to Risk of Early Death and Renal Outcomes. Blood, 2014, 124, 306-306.	4.2	4
348	A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis. Blood, 2014, 124, 35-35.	4.2	11
349	Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy. Blood, 2014, 124, 4738-4738.	4.2	3
350	Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment. Blood, 2014, 124, 4769-4769.	4.2	1
351	Risk of Progression and Survival in Newly Diagnosed Multiple Myeloma Patients Non-Responsive to Bortezomib-Based Induction Therapy: an Observational Multicenter International Study. Blood, 2014, 124, 3488-3488.	4.2	0
352	Elevated Involved Light Chains Discordant to the Increase of the Involved Heavy Chains Identifies a Subset of Multiple Myeloma Patients with Worse Outcome. Blood, 2014, 124, 2132-2132.	4.2	0
353	High Bone Turnover Is Present in Patients with Primary Systemic (AL) Amyloidosis and Increased Osteoprotegerin Identifies Patients with Poor Survival within Mayo Stage 1 Disease. Blood, 2014, 124, 2028-2028.	4.2	0
354	No Survival Improvement for Central Nervous System Multiple Myeloma By the Use of Novel Anti-Myeloma Agents: The Greek Myeloma Study Group Experience. Blood, 2014, 124, 4752-4752.	4.2	0
355	Hemodynamic, Functional and Structural Markers of Vascular Involvement in Primary Systemic Light Chain (AL) Amyloidosis. Blood, 2014, 124, 2029-2029.	4.2	0
356	The Combination of Bortezomib and Lenalidomide (VR) Consolidation Post-ASCT, in the Absence of Dexamethasone and Bisphosphonates, Improves Response Rates and Bone Metabolism in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2014, 124, 3462-3462.	4.2	0
357	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. Blood, 2014, 124, 3461-3461.	4.2	1
358	Amplification of 1q21 Is Associated with Other High Risk Cytogenetic Abnormalities and Has No Independent Prognostic Significance in Patients Treated with Novel Agents. Blood, 2014, 124, 3464-3464.	4.2	0
359	Renal Outcomes in Patients with AL Amyloidosis: Evaluation of Prognostic Factors and Impact of Therapy with Novel Agents. Blood, 2014, 124, 2130-2130.	4.2	0
360	Temporal Dynamics of Tumor-Microenvironment Interaction and Treatment Responses Revealed through Time-Lapse Compartment-Specific Bioluminescence Imaging: Translational implications. Blood, 2014, 124, 276-276.	4.2	0

#	ARTICLE	IF	CITATIONS
361	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. Blood, 2014, 124, 3404-3404.	4.2	0
362	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. Blood, 2014, 124, 2115-2115.	4.2	0
363	Translating Findings of Proteasome Inhibitors Effects from the in Vivo Drosophila Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. Blood, 2014, 124, 4814-4814.	4.2	0
364	Circulating Adamts-13 Is Reduced in Patients with Waldenstrom's Macroglobulinemia and Is Associated with Increased IgM Levels and Features of the Disease but Not with the Increased Levels of Von Willebrand Factor. Blood, 2014, 124, 5741-5741.	4.2	0
365	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. Blood, 2014, 124, 2070-2070.	4.2	0
366	Proteasome Inhibitor Therapy for Waldenstrom's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 235-237.	1.0	6
367	Current treatments for renal failure due to multiple myeloma. Expert Opinion on Pharmacotherapy, 2013, 14, 1477-1495.	2.1	29
368	Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood, 2013, 122, 3276-3282.	4.2	189
369	Response assessment in Waldenstrom macroglobulinaemia: update from the Vth International Workshop. British Journal of Haematology, 2013, 160, 171-176.	2.7	260
370	Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. OncoTargets and Therapy, 2013, , 531.	2.7	36
371	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. American Journal of Hematology, 2013, 88, 765-770.	6.5	43
372	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?. European Journal of Haematology, 2013, 91, 347-355.	1.8	43
373	A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood, 2013, 121, 3420-3427.	4.2	471
374	How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 2013, 122, 3583-3590.	4.2	294
375	VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. Leukemia, 2013, 28, 928-934.	7.7	35
376	Elevated Von Willebrand Factor Antigen Serum Levels Are Associated With Poor Prognosis In Patients With Symptomatic Waldenstrom's Macroglobulinemia. Blood, 2013, 122, 1860-1860.	4.2	2
377	Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse. Blood, 2013, 122, 1916-1916.	4.2	1
378	The Novel Proteasome Inhibitors Carfilzomib and Oprozomib Induce Milder Degenerative Effects Compared To Bortezomib When Administered Via Oral Feeding In An In Vivo Drosophila Experimental Model: A Biological Platform To Evaluate Safety/Efficacy Of Proteasome Inhibitors. Blood, 2013, 122, 1930-1930.	4.2	2

#	ARTICLE	IF	CITATIONS
379	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 1935-1935.	4.2	18
380	Skeletal-Related Events In Patients With Multiple Myeloma In The Era Of Novel Agents: Low Incidence Of Pathological Fractures After Treatment. Blood, 2013, 122, 3090-3090.	4.2	4
381	Toll-Like Receptor Activation Promotes Multiple Myeloma Cell Growth and Survival By Suppression Of Endoplasmic Reticulum Stress Factor CHOP. Blood, 2013, 122, 3112-3112.	4.2	1
382	Very Early Death (<2 months) In Myeloma Is Associated With Advanced Age, Poor Performance Status and Reduced Use Of Novel Agents, While Early Death Within 12 Months Is Associated With High Risk Features Of Both The Disease and The Patient. Blood, 2013, 122, 3195-3195.	4.2	5
383	The Cumulative Dose But Not The Frequency Of Infusions Is a Risk Factor For The Development Of Osteonecrosis Of The Jaw (ONJ) In Myeloma Patients Who Receive Zoledronic Acid (ZA). Blood, 2013, 122, 3196-3196.	4.2	1
384	Validation Of Criteria For Renal Response In Patients With Multiple Myeloma (MM) Who Present With Severe Renal Dysfunction. Blood, 2013, 122, 3176-3176.	4.2	1
385	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. Blood, 2013, 122, 1867-1867.	4.2	1
386	Competing Risk Survival Analysis In Patients With Symptomatic Waldenström's Macroglobulinemia (WM): Disease Unrelated Mortality Accounts For Differences In Survival In Patients >75 Years. Blood, 2013, 122, 3197-3197.	4.2	2
387	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. Blood, 2013, 122, 1866-1866.	4.2	0
388	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. Blood, 2013, 122, 1861-1861.	4.2	0
389	Tubular Damage Is Present In Patients With MGUS and Asymptomatic Multiple Myeloma Even In The Absence Of Impaired Estimated Glomerular Filtration Rate; Alterations Of Neutrophil Gelatinase-Associated Lipocalin and Cystatin-C In Myeloma Patients Post IMiD- and Bortezomib-Based Regimens. Blood, 2013, 122, 3091-3091.	4.2	0
390	Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients. Blood, 2013, 122, 3130-3130.	4.2	0
391	Multiple Myeloma Patients >40 Years Of Age: Clinical Characteristics and Outcome In The Era Of Novel Agents. Blood, 2013, 122, 3226-3226.	4.2	1
392	Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis Independently Of Cardiac Biomarkers. Blood, 2013, 122, 3194-3194.	4.2	0
393	Lenalidomide Administration In Patients With POEMS Syndrome. Blood, 2013, 122, 3235-3235.	4.2	1
394	Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Annals of Oncology, 2012, 23, 2681-2686.	10.0	103
395	When a little aspirin may be enough. Blood, 2012, 119, 905-906.	4.2	5
396	A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood, 2012, 119, 5384-5390.	4.2	89

#	ARTICLE	IF	CITATIONS
397	VWF, WM, and angiogenesis: is there a link?. <i>Blood</i> , 2012, 120, 3163-3164.	4.2	2
398	Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. <i>British Journal of Haematology</i> , 2012, 159, 340-351.	2.7	28
399	The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. <i>Annals of Oncology</i> , 2012, 23, 722-729.	10.0	30
400	Sclerostin: a possible target for the management of cancer-induced bone disease. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 761-769.	3.7	34
401	Evolving Chemotherapy Options for the Treatment of Myeloma Kidney: A 40-Year Perspective. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 312-323.	1.8	2
402	Prevention and Treatment of Myeloma Bone Disease. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 249-257.	2.8	11
403	Novel approaches for reducing free light chains in patients with myeloma kidney. <i>Nature Reviews Nephrology</i> , 2012, 8, 234-243.	32.8	39
404	Increased expression of cyclin D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. <i>American Journal of Hematology</i> , 2012, 87, 734-736.	6.5	10
405	Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients. <i>American Journal of Hematology</i> , 2012, 87, 861-864.	6.5	92
406	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.	1.8	35
407	Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. <i>Leukemia</i> , 2012, 27, 947-953.	7.7	151
408	The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. <i>Leukemia</i> , 2012, 27, 423-429.	7.7	149
409	Semaphorin-4D and Plexin-B1 Are Elevated in Multiple Myeloma Microenvironment and Possibly Contribute in the Development of Lytic Bone Disease. <i>Blood</i> , 2012, 120, 1819-1819.	4.2	7
410	Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.. <i>Blood</i> , 2012, 120, 2919-2919.	4.2	3
411	High Levels of Periostin in Patients with Multiple Myeloma Correlate with Low Bone Formation, Increased Fracture Rate and Diffuse MRI Pattern; Implications Into the Biology of Myeloma Bone Disease. <i>Blood</i> , 2012, 120, 3967-3967.	4.2	1
412	Lenalidomide with Low or Intermediate Dose Dexamethasone in Patients with Relapsed or Refractory Myeloma. <i>Blood</i> , 2012, 120, 4028-4028.	4.2	2
413	Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study. <i>Blood</i> , 2012, 120, 438-438.	4.2	12
414	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012, 120, 948-948.	4.2	0

#	ARTICLE	IF	CITATIONS
415	Survival until First Progression and Post First Progression Survival Equally Contribute to the Overall Survival of Myeloma Patients: Differences in Patients \geq 65 Years of Age Compared to Patients $<$ 65 Years. <i>Blood</i> , 2012, 120, 4030-4030.	4.2	1
416	The Chronic Kidney Disease-Epidemiology Collaboration-Cystatin C (CKD-EPI-CysC) Equation Has an Independent Prognostic Value for Overall Survival in Newly-Diagnosed Patients with Symptomatic Multiple Myeloma: Comparison with 3 Other Equations for GFR Estimation. <i>Blood</i> , 2012, 120, 1849-1849.	4.2	0
417	The Role of Angiopoietins System in Waldenstrom's Macroglobulinemia: Correlations with Marrow Microvessel Density and Survival. <i>Blood</i> , 2012, 120, 3901-3901.	4.2	1
418	Outcomes of Primary Systemic Light Chain (AL) Amyloidosis in Patients Treated Upfront with Novel Agents and the Importance of Risk Adapted Treatment Strategies. <i>Blood</i> , 2012, 120, 1786-1786.	4.2	1
419	High C-Terminal Cross-Linking Telopeptide of Collagen Type-I (CTX) Predicts for Poor Overall Survival in Patients with Multiple Myeloma Who Receive Frontline Therapy with Immunomodulatory Drugs (IMiDs) but Not with Bortezomib-Based Regimens. <i>Blood</i> , 2012, 120, 935-935.	4.2	1
420	Increased Serum Lactate Dehydrogenase Should Be Included Among the Variables That Define Very-High-Risk Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 409-413.	1.0	43
421	Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. <i>Leukemia and Lymphoma</i> , 2011, 52, 2299-2303.	1.4	29
422	Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 115-117.	1.0	10
423	Prognostication of the High-Risk WM Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 127-129.	1.0	2
424	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	33.7	2,665
425	Systemic Chemotherapy with Pemetrexed and Cisplatin for Malignant Peritoneal Mesothelioma: A Single Institution Experience. <i>Tumori</i> , 2011, 97, 25-29.	1.4	17
426	Bortezomib for AL amyloidosis: moving forward. <i>Blood</i> , 2011, 118, 827-828.	4.2	20
427	Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. <i>European Journal of Haematology</i> , 2011, 87, 323-329.	1.8	9
428	No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years. <i>American Journal of Hematology</i> , 2011, 86, 479-483.	6.5	45
429	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	6.5	16
430	Circulating Periostin Is Elevated in Patients with Multiple Myeloma and Correlates with Advanced Disease Features and High Bone Resorption. <i>Blood</i> , 2011, 118, 3922-3922.	4.2	12
431	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5083-5083.	4.2	10
432	Patients with POEMS Syndrome Have High Bone Turnover and Increased Circulating Angiogenic Cytokines; Should Angiopoietin-2 and Bone-Specific Alkaline Phosphatase Be Used As Minor Criteria for the Diagnosis of the Disease?. <i>Blood</i> , 2011, 118, 806-806.	4.2	1

#	ARTICLE	IF	CITATIONS
433	European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease. <i>Blood</i> , 2011, 118, 995-995.	4.2	5
434	The Role of Novel Agents on Reversibility of Renal Impairment in Newly Diagnosed Patients with Multiple Myeloma; a Single Center Experience on 112 Patients. <i>Blood</i> , 2011, 118, 3961-3961.	4.2	1
435	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5084-5084.	4.2	5
436	Characteristics and Clinical Course of Myeloma in Patients 40 Years of Age or Younger: A Study of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5085-5085.	4.2	0
437	Comparison of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD) Study Equations and A Formula Based on Cystatin-C and Serum Creatinine for the Estimation of Glomerular Filtration Rate in Patients with Multiple Myeloma; Is It Time to Change From MDRD to CKD-EPI Equation?. <i>Blood</i> , 2011, 118, 5091-5091.	4.2	0
438	Effect of Circulating CCL3, Which Is Produced by Malignant Cells of Waldenström's Macroglobulinemia, on Patients' Survival. <i>Blood</i> , 2011, 118, 2894-2894.	4.2	0
439	Extensive Bone Marrow Infiltration and Abnormal Free Light Chain Ratio Identifies Patients with Smoldering Myeloma At High Risk for Progression to Symptomatic Disease. <i>Blood</i> , 2011, 118, 3926-3926.	4.2	0
440	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011, 118, 1409-1409.	4.2	0
441	Circulating Angiogenic Cytokines Are Elevated in Patients with Smoldering Myeloma; Implications Into Disease Biology. <i>Blood</i> , 2011, 118, 5059-5059.	4.2	0
442	Diffuse Pattern of Bone Marrow Involvement in MRI Is Associated with High Risk Cytogenetics and Poor Outcome in Newly Diagnosed, Symptomatic Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 3920-3920.	4.2	0
443	Low Circulating Mannan-Binding Leptin Levels Correlate with Increased Number of Febrile Episodes in Myeloma Patients Who Undergo High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplantation and Do Not Receive Antibiotic Prophylaxis. <i>Blood</i> , 2011, 118, 4457-4457.	4.2	0
444	Prospective Evaluation of the Risk of Thromboembolic Complications in Patients Treated with Lenalidomide-based Therapy and Genetic Associations. <i>Blood</i> , 2011, 118, 2872-2872.	4.2	0
445	Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome. <i>Blood</i> , 2011, 118, 1802-1802.	4.2	0
446	Bone Marrow Biopsy May Be Required During the Initial Evaluation of Individuals with Asymptomatic Monoclonal Gammopathy. <i>Blood</i> , 2011, 118, 5067-5067.	4.2	0
447	Deletion 17p in Unselected Newly Diagnosed Symptomatic Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 5081-5081.	4.2	0
448	High Circulating Vascular Endothelial Growth Factor Receptor-1 Correlates with Increased Microvessel Density and Inferior Survival in Newly-Diagnosed Patients with Multiple Myeloma Who Receive Frontline Therapy with Novel Agent-Based Regimens. <i>Blood</i> , 2011, 118, 5082-5082.	4.2	0
449	High Frequency of Monoclonal Immunoglobulins Exhibiting Natural Autoantibody-Like Activity in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2011, 118, 2893-2893.	4.2	1
450	Effect of Amp5q31 and Del12p13 on Survival of Patients with Multiple Myeloma Treated with Novel Agent-Based Regimens: A Single Center Experience on 172 Patients. <i>Blood</i> , 2011, 118, 1811-1811.	4.2	0

#	ARTICLE	IF	CITATIONS
451	Mobilization of Autologous Peripheral Blood Stem Cells with Spectra Optia v5.0: A Single Center Experience with An Automatic Interface-Controlled Apheresis System. <i>Blood</i> , 2011, 118, 4396-4396.	4.2	0
452	Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma. <i>Blood</i> , 2011, 118, 3918-3918.	4.2	0
453	Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. <i>European Journal of Haematology</i> , 2010, 85, 1-5.	1.8	45
454	Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem cell transplantation: Results of a single institution, randomized phase 2 trial. <i>American Journal of Hematology</i> , 2010, 85, 863-867.	6.5	47
455	High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. <i>Leukemia Research</i> , 2010, 34, 399-402.	0.7	27
456	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <i>Leukemia Research</i> , 2010, 34, 1340-1343.	0.7	59
457	Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. <i>Leukemia Research</i> , 2010, 34, 1395-1397.	0.7	66
458	Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. <i>Leukemia</i> , 2010, 24, 1769-1778.	7.7	124
459	Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. <i>Leukemia</i> , 2010, 24, 1206-1212.	7.7	67
460	Systemic Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1912-1915.	4.2	1
461	Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 56-61.	1.0	18
462	Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 110-117.	1.0	21
463	Validation of the Criteria of Response to Treatment In AL Amyloidosis. <i>Blood</i> , 2010, 116, 1364-1364.	4.2	21
464	Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma: Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib. <i>Blood</i> , 2010, 116, 2963-2963.	4.2	7
465	Elevated Levels of Circulating Activin-A Correlate with Features of Advanced Disease, Extensive Bone Involvement and Inferior Survival In Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 2967-2967.	4.2	4
466	Elevated Serum Lactate Dehydrogenase (LDH) Should Be Included Among the Variables Which Define High Risk Multiple myeloma. <i>Blood</i> , 2010, 116, 2969-2969.	4.2	6
467	Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients Who Are Treated Upfront with Novel Agent-Based Regimens. <i>Blood</i> , 2010, 116, 3033-3033.	4.2	1
468	The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD) Tj ETQq0 0 0 rgBT /Overlock 10 T Prospective Multicenter Study. <i>Blood</i> , 2010, 116, 3052-3052.	4.2	3

#	ARTICLE	IF	CITATIONS
469	A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis. <i>Blood</i> , 2010, 116, 988-988.	4.2	25
470	Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis. <i>Blood</i> , 2010, 116, 3048-3048.	4.2	0
471	Development of New Treatment Strategies Targeting Clonogenic and Tumorigenic Myeloma Side Population.. <i>Blood</i> , 2010, 116, 1581-1581.	4.2	0
472	Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network. <i>Blood</i> , 2010, 116, 1941-1941.	4.2	3
473	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor " Microenvironment Interactions.. <i>Blood</i> , 2010, 116, 1574-1574.	4.2	28
474	Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma Who Are Older Than 65 Years. <i>Blood</i> , 2010, 116, 1947-1947.	4.2	0
475	Increased Expression of Cyclin-D1 on Trepine Bone Marrow Biopsies Independently Predicts for Shorter Overall Survival In Patients with Multiple Myeloma Treated with Novel Agents. <i>Blood</i> , 2010, 116, 2965-2965.	4.2	0
476	Reduced Repair Efficiency Correlates with Increased Cellular Chemosensitivity and Better Response to High Dose Melphalan of Patients with Multiple Myeloma. <i>Blood</i> , 2010, 116, 2976-2976.	4.2	0
477	Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy. <i>Blood</i> , 2010, 116, 3035-3035.	4.2	0
478	Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 120-126.	16.9	211
479	Somatic mutations of adenomatous polyposis coli gene and nuclear "catenin accumulation have prognostic significance in invasive urothelial carcinomas: Evidence for Wnt pathway implication. <i>International Journal of Cancer</i> , 2009, 124, 103-108.	4.3	58
480	Targeted therapies in multiple myeloma. <i>Targeted Oncology</i> , 2009, 4, 23-36.	3.2	31
481	Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). <i>Leukemia</i> , 2009, 23, 1152-1157.	7.7	180
482	Increased expression of macrophage inflammatory protein-1" on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009, 23, 2177-2181.	7.7	57
483	Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 302-306.	1.8	105
484	Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. <i>Annals of Oncology</i> , 2009, 20, 117-120.	10.0	371
485	Treatment of Relapsed/Refractory Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 143-157.	3.1	50
486	The Addition of Bortezomib to the Combination of Lenalidomide and Dexamethasone Increases Bone Formation in Relapsed/Refractory Myeloma: a Prospective Study in 91 Patients.. <i>Blood</i> , 2009, 114, 1815-1815.	4.2	6

#	ARTICLE	IF	CITATIONS
487	Consolidation Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) Regimen After ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Reduces Bone Resorption and RANKL/OPG Ratio but Seems to Have No Effect On Bone Formation and Angiogenesis.. Blood, 2009, 114, 3863-3863.	4.2	2
488	High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.. Blood, 2009, 114, 425-425.	4.2	13
489	A Phase I/II Study of Lenalidomide (R) with Low Dose Dexamethasone (d) and Cyclophosphamide (C) for Patients with Primary Systemic (AL) Amyloidosis.. Blood, 2009, 114, 428-428.	4.2	3
490	Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications.. Blood, 2009, 114, 954-954.	4.2	2
491	Reversibility of Renal Failure in Newly Diagnosed Patients with Multiple Myeloma and the Role of Novel Agents.. Blood, 2009, 114, 955-955.	4.2	1
492	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities.. Blood, 2009, 114, 958-958.	4.2	5
493	Increased levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Inter-Cellular Adhesion Molecule-1 (ICAM-1) Correlate with Advanced Disease Features and Poor Survival in Newly Diagnosed Patients with Multiple Myeloma. Reduction Post-Bortezomib- and Lenalidomide-Based Regimens.. Blood, 2009, 114, 1824-1824.	4.2	0
494	Antibacterial Prophylaxis Reduces the Incidence of Neutropenic Fever and the Rate of Infections in Patients with Multiple Myeloma Who Undergo An Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3334-3334.	4.2	0
495	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM) and the Importance of Serum Lactate Dehydrogenase (LDH).. Blood, 2009, 114, 2845-2845.	4.2	0
496	The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.. Blood, 2009, 114, 2279-2279.	4.2	0
497	Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.. Blood, 2009, 114, 3871-3871.	4.2	0
498	Diffuse MRI Marrow Pattern Correlates with Increased Angiogenesis, Advanced Disease Features and Poor Prognosis in Newly-Diagnosed Patients with Multiple Myeloma Treated with Novel Agents.. Blood, 2009, 114, 829-829.	4.2	0
499	The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies.. Blood, 2009, 114, 730-730.	4.2	0
500	Treatment of plasma cell dyscrasias with lenalidomide. Leukemia, 2008, 22, 1343-1353.	7.7	42
501	Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008, 22, 1485-1493.	7.7	276
502	The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 2008, 22, 2247-2256.	7.7	120
503	Schnitzler's Syndrome: Increased Levels of Bone Formation and Angiogenesis Factors Are Reduced After Successful Pefloxacin Treatment. Clinical Lymphoma and Myeloma, 2008, 8, 359-362.	1.8	13
504	Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leukemia and Lymphoma, 2008, 49, 890-895.	1.4	76

#	ARTICLE	IF	CITATIONS
505	Mantle-Cell Lymphoma (Multiple Lymphomatous Polyposis) of the Entire GI Tract. <i>Journal of Clinical Oncology</i> , 2008, 26, 1555-1557.	16.9	24
506	The role of novel drugs in multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, vii121-vii127.	10.0	6
507	Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5904-5909.	16.9	143
508	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. <i>Blood</i> , 2008, 112, 1725-1725.	4.2	3
509	Bortezomibâ€“Melphalanâ€“Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. <i>Blood</i> , 2008, 112, 1727-1727.	4.2	5
510	Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).. <i>Blood</i> , 2008, 112, 1734-1734.	4.2	1
511	Significant Activity of Bortezomib-Based Therapy in Patients with Primary Systemic (AL) Amyloidosis. <i>Blood</i> , 2008, 112, 869-869.	4.2	6
512	Increased Levels of Serum Tissue Inhibitor of Metalloproteinase-1 Correlate with Advanced Stage, Increased Bone Resorption, Lytic Bone Disease and Poor Survival in Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2008, 112, 5143-5143.	4.2	0
513	Osteopontin Predicts for Survival and Cystatin C-Based Estimated GFR Predicts for Renal Response to Therapy in Patients with Primary Systemic Amyloidosis. <i>Blood</i> , 2008, 112, 2731-2731.	4.2	0
514	Strong Correlation Between Angiogenesis and Macrophage Counts in Waldenstromâ€™s Macroglobulinemia: Implications into the Biology of the Disease. <i>Blood</i> , 2008, 112, 5108-5108.	4.2	0
515	Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG). <i>Blood</i> , 2008, 112, 655-655.	4.2	0
516	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. <i>Blood</i> , 2008, 112, 5119-5119.	4.2	0
517	The Administration of Bortezomib, Dexamethasone and Thalidomide (VTD) after ASCT in Myeloma Patients Who Do Not Receive Bisphosphonates Normalizes sRANKL, Dickkopf-1 and Improves Abnormal Osteoclast Function and Impaired Angiogenesis.. <i>Blood</i> , 2008, 112, 1728-1728.	4.2	0
518	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. <i>Blood</i> , 2008, 112, 1726-1726.	4.2	0
519	The evolving role of lenalidomide in the treatment of hematologic malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 497-509.	2.1	47
520	Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. <i>Leukemia and Lymphoma</i> , 2007, 48, 754-758.	1.4	16
521	Management of Relapsed and Relapsed Refractory Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1175-1215.	2.2	8
522	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factorâ€“B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007, 46, 221-229.	1.8	85

#	ARTICLE	IF	CITATIONS
523	Thalidomide in the treatment of multiple myeloma. Best Practice and Research in Clinical Haematology, 2007, 20, 681-699.	1.7	19
524	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. British Journal of Haematology, 2007, 137, 560-568.	2.7	38
525	The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. Gynecologic Oncology, 2007, 104, 372-376.	3.0	20
526	Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.. Blood, 2007, 110, 1484-1484.	4.2	6
527	Treatment of Light Chain (AL) Amyloidosis and Light Chain Deposition Disease (LCDD) with the Combination of Bortezomib and Dexamethasone.. Blood, 2007, 110, 191-191.	4.2	1
528	Treatment of Patients with Multiple Myeloma Complicated by Renal Failure with Bortezomib - Based Regimens.. Blood, 2007, 110, 2739-2739.	4.2	2
529	Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).. Blood, 2007, 110, 3519-3519.	4.2	11
530	The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.. Blood, 2007, 110, 3596-3596.	4.2	2
531	Decreased Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Multiple Myeloma (MM) Treated with Zoledronic Acid (ZA) after Application of Preventive Measures.. Blood, 2007, 110, 3609-3609.	4.2	3
532	Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.. Blood, 2007, 110, 4745-4745.	4.2	1
533	Thalidomide Based Regimens (TBR) for Relapsed/Refractory Multiple Myeloma Patients: Long Term Follow Up, Unmaintained Remissions and Disease Control after Subsequent Treatments.. Blood, 2007, 110, 4812-4812.	4.2	0
534	The International Prognostic Scoring System for Waldenstrom's Macroglobulinemia (ISSWM) Is Applicable in Patients Treated with Rituximab-Based Regimens.. Blood, 2007, 110, 3615-3615.	4.2	0
535	High Serum Levels of Angiogenic Cytokines in AL Amyloidosis Correlates with Disease Features.. Blood, 2007, 110, 4781-4781.	4.2	0
536	Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.. Blood, 2007, 110, 4729-4729.	4.2	0
537	The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.. Blood, 2007, 110, 1478-1478.	4.2	0
538	Symptomatic Waldenstrom's Macroglobulinemia (WM) in Young Patients: Disease Characteristics and Outcome.. Blood, 2007, 110, 4730-4730.	4.2	0
539	Angiogenetic Factors and Biochemical Markers of Bone Metabolism in POEMS Syndrome Treated with High-Dose Therapy and Autologous Stem Cell Support. Clinical Lymphoma and Myeloma, 2006, 7, 73-76.	1.8	19
540	Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. International Journal of Gynecological Cancer, 2006, 16, 994-999.	2.7	26

#	ARTICLE	IF	CITATIONS
541	Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , 2006, 133, 301-304.	2.7	24
542	Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 102, 124-127.	3.0	16
543	The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2006, 106, 297-303.	4.0	79
544	Hematological malignancies: myeloma. <i>Annals of Oncology</i> , 2006, 17, x136-x143.	10.0	8
545	Carboplatin Hypersensitivity Reactions: A Single Institution Experience. <i>Journal of Chemotherapy</i> , 2005, 17, 104-110.	1.5	16
546	A Phase II Study of Capecitabine Plus Oxaliplatin (XELOX): A New First-Line Option in Metastatic Colorectal Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2005, 35, 103-110.	1.0	30
547	Clinicopathological features of ovarian carcinosarcomas: a single institution experience. <i>Gynecologic Oncology</i> , 2005, 96, 136-142.	3.0	39
548	The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. <i>Gynecologic Oncology</i> , 2005, 99, 376-382.	3.0	45
549	Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. <i>Cancer</i> , 2005, 103, 2629-2635.	4.0	59
550	The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. <i>Annals of Oncology</i> , 2005, 16, 307-313.	10.0	66
551	Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group. <i>Annals of Oncology</i> , 2005, 16, 773-779.	10.0	15
552	Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors. <i>Journal of Clinical Oncology</i> , 2005, 23, 8580-8587.	16.9	1,030
553	Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment. <i>Urology</i> , 2005, 65, 126-130.	1.4	26
554	Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. <i>Leukemia and Lymphoma</i> , 2004, 45, 2275-2279.	1.4	15
555	Adjuvant Chemotherapy With Paclitaxel and Carboplatin in Patients With Advanced Carcinoma of the Upper Urinary Tract: A Study by the Hellenic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 2150-2154.	16.9	88
556	A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. <i>Annals of Oncology</i> , 2004, 15, 1250-1255.	10.0	30
557	Efficacy and safety of elotuzumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 0, , 1-9.	2.6	5
558	Managing complications secondary to Waldenström's macroglobulinemia. <i>Expert Review of Hematology</i> , 0, 14, 621-632.	2.0	0

#	ARTICLE	IF	CITATIONS
559	Targeting BCL2 in Waldenström macroglobulinemia: from biology to treatment management. <i>Frontiers in Oncology</i> , 0, 15, .	2.6	0
560	Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 0, 207, 1589-1593.	2.7	0
561	Determinants of 15-Year Progression-Free Survival in Multiple Myeloma; Real-World Data From a Single Institution. <i>American Journal of Hematology</i> , 0, 100, 1747-1759.	6.5	4
562	Genomic landscape of IgM-MGUS and patients with stable or progressive asymptomatic Waldenström macroglobulinemia. <i>Blood</i> , 0, 146, 3086-3097.	4.2	3
563	Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies. <i>Blood Cancer Journal</i> , 0, 15, .	5.5	0
564	Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy. <i>American Journal of Hematology</i> , 0, 101, 56-69.	6.5	2
565	Easy Proteomics Sample Preparation: Technical Repeatability and Workflow Optimization Across 8 Biological Matrices in a New Core Facility Setting. <i>Proteomics</i> , 0, 25, 15-24.	3.1	0
566	Bone disease burden does not impact overall survival in newly diagnosed patients with multiple myeloma at a single center, retrospective imaging analysis on 119 patients. <i>Journal of Bone Oncology</i> , 0, 55, 100720.	3.0	0
567	Cold pressor test and paradoxical blood pressure reduction in light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 0, , 1-11.	4.6	0
568	Temporal trends in progression risk in smoldering myeloma: a systematic review. <i>EClinicalMedicine</i> , 0, 91, 103750.	8.2	0
569	Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma. <i>Nature Medicine</i> , 0, 32, 964-977.	33.0	1
570	Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis. <i>Current Problems in Cardiology</i> , 0, 51, 103265.	3.0	0
571	Clinical outcomes in newly diagnosed patients with Waldenström's macroglobulinaemia treated in a tertiary academic centre. <i>British Journal of Haematology</i> , 0, 208, 937-946.	2.7	0